Peptide binding to HLA class i molecules: Homogenous, high-throughput screening, and affinity assays

Journal of Biomolecular Screening

Volumn 14, Issue 2, 2009, Pages 173-180

  Harndahl, Mikkel ^a   Justesen, Sune ^a   Lamberth, Kasper ^a   Røder, Gustav ^a   Nielsen, Morten ^b   Buus, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

AlphaScreen ., ; High throughput screening; Homogeneous assay; LOCI; Peptide HLA interaction

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BIOTINYLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MICE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

EID: 61849124792     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108329453     Document Type: Article

References (13)

1. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994 ; 153: 5586-5592.
2. Nielsen M., Lundegaard C., Blicher T., Lamberth K., Harndahl M., Justesen S., et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2007 ; 2: e796.
3. Ullman EF, Kirakossian H., Singh S., Wu ZP, Irvin BR, Pease JS, et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci U S A 1994 ; 91: 5426-5430.
4. Ullman EF, Kirakossian H., Switchenko AC, Ishkanian J., Ericson M., Wartchow CA, et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996 ; 42: 1518-1526.
5. Gabriel D., Vernier M., Pfeifer MJ, Dasen B., Tenaillon L., Bouhelal R.: High throughput screening technologies for direct cyclic AMP measurement. Assay Drug Dev Technol 2003 ; 1: 291-303.
6. Wu X., Glickman JF, Bowen BR, Sills MA: Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J Biomol Screen 2003 ; 8: 381-392.
7. Poulsen F., Jensen KB: A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen 2007 ; 12: 240-247.
8. Szekeres PG, Leong K., Day TA, Kingston AE, Karran EH: Development of homogeneous 384-well high-throughput screening assays for A21-40 and A21-42 using AlphaScreenĝ.,¢ technology. J Biomol Screen 2008 ; 13: 101-111.
9. Ostergaard Pedersen L., Nissen MH, Hansen NJ, Nielsen LL, Lauemãller SL, Blicher T., et al. Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol 2001 ; 31: 2986-2996.
10. Leisner C., Loeth N., Lamberth K., Justesen S., Sylvester-Hvid C., Schmidt EG, et al. One-pot, mix-and-read peptide-MHC tetramers. PLoS ONE 2008 ; 3: e1678.
11. Parham P., Barnstable CJ, Bodmer WF: Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol 1979 ; 123: 342-349.
12. Sylvester-Hvid C., Kristensen N., Blicker T., Ferre H., Lauemãller SL, Wolff XA, et al. Establishment of a quantitative ELISA capable of determining peptide-MHC class I interaction. Tissue Antigens 2002 ; 59: 251-258.
13. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.